Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15912307rdf:typepubmed:Citationlld:pubmed
pubmed-article:15912307lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C0028005lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C0205160lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C0439851lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C1552596lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C1947931lld:lifeskim
pubmed-article:15912307lifeskim:mentionsumls-concept:C0378675lld:lifeskim
pubmed-article:15912307pubmed:issue3lld:pubmed
pubmed-article:15912307pubmed:dateCreated2005-5-24lld:pubmed
pubmed-article:15912307pubmed:abstractTextWe encountered a 91-year-old woman with atrial fibrillation complicating bradycardia while she was receiving therapy with an L/N-type calcium channel blocker, cilnidipine, for hypertension, which is an unusual observation for the dihydropyridine class of calcium channel blockers. Therefore, we compared the dromotropic effect of cilnidipine with that of an L-type calcium channel blocker, nicardipine, which has a similar hypotensive activity. The canine isolated, blood-perfused atrioventricular node preparation was used. Cilnidipine as well as nicardipine slowed atrioventricular nodal conduction in a dose-related manner. However, the dromotropic action of cilnidipine was about five times less potent than that of nicardipine. These experimental results may suggest that we experienced an atypical clinical event of cilnidipine in a very old woman; otherwise one can speculate that the N-type calcium channel inhibitory component of cilnidipine might have played a role in exerting the negative dromotropic effect in this patient.lld:pubmed
pubmed-article:15912307pubmed:languageenglld:pubmed
pubmed-article:15912307pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15912307pubmed:citationSubsetIMlld:pubmed
pubmed-article:15912307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15912307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15912307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15912307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15912307pubmed:statusMEDLINElld:pubmed
pubmed-article:15912307pubmed:monthMaylld:pubmed
pubmed-article:15912307pubmed:issn0910-8327lld:pubmed
pubmed-article:15912307pubmed:authorpubmed-author:HashimotoKeit...lld:pubmed
pubmed-article:15912307pubmed:authorpubmed-author:TakaharaAkira...lld:pubmed
pubmed-article:15912307pubmed:authorpubmed-author:NakamuraYujiYlld:pubmed
pubmed-article:15912307pubmed:authorpubmed-author:SugiyamaAtsus...lld:pubmed
pubmed-article:15912307pubmed:authorpubmed-author:SatohYoshioki...lld:pubmed
pubmed-article:15912307pubmed:authorpubmed-author:AndoKentaroKlld:pubmed
pubmed-article:15912307pubmed:issnTypePrintlld:pubmed
pubmed-article:15912307pubmed:volume20lld:pubmed
pubmed-article:15912307pubmed:ownerNLMlld:pubmed
pubmed-article:15912307pubmed:authorsCompleteYlld:pubmed
pubmed-article:15912307pubmed:pagination112-5lld:pubmed
pubmed-article:15912307pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:meshHeadingpubmed-meshheading:15912307...lld:pubmed
pubmed-article:15912307pubmed:year2005lld:pubmed
pubmed-article:15912307pubmed:articleTitleComparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.lld:pubmed
pubmed-article:15912307pubmed:affiliationDepartment of Pharmacology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Tamaho-cho, Nakakoma-gun, Yamanashi, 409-3898, Japan. atsushis@yamanashi.ac.jplld:pubmed
pubmed-article:15912307pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15912307pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15912307pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:15912307pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed